Home › Funds › Palo Alto Investors LP › ANAB
Palo Alto Investors LP position in ANAB
ANAPTYSBIO INC · Health Care
Palo Alto Investors LP reported holding 595,264 shares of ANAB (ANAPTYSBIO INC) in its Q3 2026 13F filing — a position valued at US$29.9M, representing 4.45% of its reported portfolio and ranking #10 among its reported holdings. Palo Alto Investors LP has disclosed ANAB holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Palo Alto Investors LP's ANAB position evolved
Palo Alto Investors LP first disclosed a stake in ANAB in Q3 2023 at 431,224 shares (US$7.7M). The position peaked in Q2 2026 at 603,489 shares, worth US$40.7M. Across 13 filings, Palo Alto Investors LP increased the stake 5 time(s), trimmed it 5 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 595,264 shares valued at US$29.9M — a reduction of -8,225 shares quarter over quarter.. Notable position changes include a 59% increase in Q4 2023 (shares rose 5% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 431.22K | $7.74M | New |
| Q4 2023 | 686.88K | $14.71M | Add |
| Q1 2024 | 799.91K | $18.01M | Add |
| Q2 2024 | 803.64K | $20.14M | Hold |
| Q3 2024 | 843.97K | $28.27M | Add |
| Q4 2024 | 843.97K | $11.17M | Hold |
| Q1 2025 | 1.02M | $18.98M | Add |
| Q2 2025 | 812.82K | $18.04M | Reduce |
| Q3 2025 | 673.52K | $20.62M | Reduce |
| Q4 2025 | 690.03K | $33.45M | Add |
| Q1 2026 | 638.16K | $35.39M | Reduce |
| Q2 2026 | 603.49K | $40.74M | Reduce |
| Q3 2026 | 595.26K | $29.92M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ANAB and 13F data
ANAB (ANAPTYSBIO INC) is a Health Care company. 37 other funds we track also report a position in ANAB — the largest reported positions include EcoR1 Capital, LLC (US$396.1M), TANG CAPITAL MANAGEMENT LLC (US$74.1M), Sanofi (US$41.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ANAB
- EcoR1 Capital, LLC 7.88M sh · $396.05M · Q3 2026
- TANG CAPITAL MANAGEMENT LLC 1.47M sh · $74.10M · Q3 2026
- Sanofi 821.92K sh · $41.31M · Q3 2026
- 683 Capital Management, LLC 740.00K sh · $37.19M · Q3 2026
- Pertento Partners LLP 545.00K sh · $27.39M · Q3 2026
- APIS CAPITAL ADVISORS, LLC 444.00K sh · $22.32M · Q3 2026
- Sofinnova Investments, Inc. 330.40K sh · $16.61M · Q3 2026
- First Light Asset Management, LLC 328.52K sh · $16.51M · Q3 2026
- Irenic Capital Management LP 299.21K sh · $15.04M · Q3 2026
More on Palo Alto Investors LP
FAQ
How long has Palo Alto Investors LP held ANAB?
Palo Alto Investors LP has disclosed ANAB holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Palo Alto Investors LP's current position in ANAB?
As of Q3 2026, Palo Alto Investors LP holds 595.26K shares of ANAB (ANAPTYSBIO INC), valued at $29.92M, representing 4.45% of its reported portfolio and ranking #10.
Has Palo Alto Investors LP been buying or selling ANAB?
In the latest 13F filing (Q3 2026), Palo Alto Investors LP reduced its position in ANAB. The position peaked in Q2 2026 at 603.49K shares.
Which other funds hold ANAB?
Other major institutional holders of ANAB include EcoR1 Capital, LLC, TANG CAPITAL MANAGEMENT LLC, Sanofi, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.